CVD and Stroke protocols
In this section of our website, you will be able to find links to key documents including patient information leaflets.
Archived documents
- 13. Review of Cardiac Rehabilitation Provision in Cheshire & Merseyside 2014
- 17. Planned DCCV in Clinic as Elective Out-Patient with Atrial Fibrillation/Flutter
Documents due for review as of November 2022
- 1. Guidelines for the Administration of Intravenous and Subcutaneous diuretics for Heart Failure Patients in the Community Setting
- 4. Clinical Preceptor Program
Reviewed/Current documentation
- 2. Pathway to improve access to emergency angiography for comatose patients following cardiac arrest due to myocardial infarction in Cheshire and Merseyside
- 3. Primary Percutaneous Coronary Intervention (PPCI) Protocol
- 6. Patient information leaflet Apixaban V2.0 March 2023
- 7. Patient information leaflet Dabigatran V2.0 March 2023
- 8. Patient information leaflet Edoxaban V2.0 March 2023
- 9. Patient information leaflet Rivaroxaban V2.0 March 2023
- 11. Clinical pathway or people with atrial fibrillation or at risk of atrial fibrillation
- 12. Cheshire and Merseyside Heart Failure Competency record
- 14. Sacubitril/Valsartan (Entresto®) treatment algorithm
- 15. Statement on the use of Sacubitril/Valsartan (Entresto ®) for the treatment of symptomatic chronic heart failure with reduced ejection fraction
- 16. GP Communication Letter Sacubitril/Valsartan (Entresto ®)
- 22. Statement on the use of Sacubitril/Valsartan (Entresto ®) for the treatment of symptomatic chronic heart failure with reduced ejection fraction
- 23. Cheshire and Mersey Decision Aid for Initiating a DOAC in AF Sept 22
- 24. Cheshire and Mersey DOAC cover note
- 27. Cheshire and Merseyside FAQ – Medicines Optimisation of DOACs in AF
- 28. Cheshire and Mersey Decision Aid for Medicines Optimisation Review of Patients Prescribed Apixaban Sept 2022
- 29. Updated SOP – Cheshire and Mersey Medicine optimisation of DOACs and review to change agent
- 30. BP Opportunistic Testing Guideline V2.3
- 31. Lifespan Pathway for Lipid Management 2024